A review of the logistic role of l-carnitine in the management of radiation toxicity and radiotherapy side effects

Journal of Applied Toxicology

Volumn 31, Issue 8, 2011, Pages 707-713

  Khan, Haseeb Ahmad ^a   Alhomida, Abdullah Saleh ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adverse effects; Biomarker; Carnitine; Prognosis; Prophylaxis; Radiation therapy

Indexed keywords

ACETYLCARNITINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARNITINE; CATALASE; CISPLATIN; CYCLOPHOSPHAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SUPEROXIDE DISMUTASE; TRASTUZUMAB;

ADJUVANT THERAPY; ANEMIA; APOPTOSIS; BREAST CANCER; BREAST SARCOMA; CACHEXIA; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARNITINE DEFICIENCY; CATARACT; CELL DEATH; CHEMORADIOTHERAPY; COCHLEA INJURY; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DIETARY INTAKE; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MEGADOSE; ENERGY METABOLISM; ENERGY YIELD; EXCISION REPAIR; FATIGUE; FATTY ACID OXIDATION; FOLLOW UP; GAMMA IRRADIATION; GENOMIC INSTABILITY; HAIR LOSS; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; INFERTILITY; IONIZING RADIATION; LIPID PEROXIDATION; LIVER CANCER; LIVER CARCINOGENESIS; LUNG TOXICITY; MISMATCH REPAIR; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RADIATION TOXICITY; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SECOND CANCER; SKIN IRRITATION; SPERMATOGENESIS; TESTIS CANCER;

ANIMALS; BIOLOGICAL MARKERS; CARNITINE; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HUMANS; NEOPLASMS; PROGNOSIS; RADIATION INJURIES; RADIATION ONCOLOGY; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; VITAMIN B COMPLEX;

ANIMALIA;

EID: 81455131665     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1716     Document Type: Review

References (98)

1. Abdelrazik H, Sharma R, Mahfouz R, Agarwal A. 2009. l-Carnitine decreases DNA damage and improves the in vitro blastocyst development rate in mouse embryos. Fertil. Steril. 91: 589-596.
2. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, Al-Shabanah OA, Sayed-Ahmed MM. 2009. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J. Gastroenterol. 15: 1373-1380.
3. Altas E, Ertekin MV, Gundogdu C, Demirci E. 2006. l-Carnitine reduces cochlear damage induced by gamma irradiation in guinea pigs. Ann. Clin. Lab. Sci. 36: 312-318.
4. Altun ZS, Güneş D, Aktaş S, Erbayraktar Z, Olgun N. 2010. Protective effects of acetyl-l-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem. Res. 35: 437-443.
5. Aouida M, Poulin R, Ramotar D. 2010. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J. Biol. Chem. 285: 6275-624.
6. Armstrong GT, Stovall M, Robison LL. 2010. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat. Res. 174: 840-850.
7. Athar BS, Paganetti H. 2011. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother. Oncol. 98: 87-92.
8. Aziz K, Nowsheen S, Georgakilas AG. 2010. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr. Mol. Med. 10: 626-639.
9. Badie C, Dziwura S, Raffy C, Tsigani T, Alsbeih G, Moody J, Finnon P, Levine E, Scott D, Bouffler S. 2008. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. Br. J. Cancer 98: 1845-1851.
10. Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers R, Leisenring W, Mertens AC, Hammond S, Friedman DL, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Robison LL, Inskip PD. 2010. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat. Res. 174: 741-752.
11. Biagioli MC, Hoffe SE. 2010. Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control 17: 223-232.
12. Bolling T, Kreuziger DC, Ernst I, Elsayed H, Willich N. 2011. Retrospective, monocentric analysis of late effects after total body irradiation (TBI) in adults. Strahlenther. Onkol. 187: 311-315.
13. Buonanno M, de Toledo SM, Pain D, Azzam EI. 2011. Long-term consequences of radiation-induced bystander effects depend on radiation quality and dose and correlate with oxidative stress. Radiat. Res. 175: 405-415.
14. Busia A, Laffranchi A, Viviani S, Bonfante V, Villani F. 2010. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Anticancer Res. 30: 4381-4387.
15. Calo LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, Pessina AC. 2006. Antioxidant effect of l-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int. J. Cardiol. 107: 54-60.
16. Caloglu M, Yurut-Caloglu V, Durmus-Altun G, Oz-Puyan F, Ustun F, Cosar-Alas R, Saynak M, Parlar S, Turan FN, Uzal C. 2009. Histopathological and scintigraphic comparisons of the protective effects of l-carnitine and amifostine against radiation-induced late renal toxicity in rats. Clin. Exp. Pharmacol. Physiol. 36: 523-530.
17. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. 2007. Pharmacologic treatment of cancer-related fatigue. Oncologist 12(suppl. 1): 43-51.
18. Cavaliere R, Schiff D. 2006. Neurologic toxicities of cancer therapies. Curr. Neurol. Neurosci. Rep. 6: 218-226.
19. Chang B, Nishikawa M, Nishiguchi S, Inoue M. 2005. l-Carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer 113: 719-729.
20. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esteban-Cruciani N. 2009. l-Carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J. Pain Symptom Mgmt 37: 622-631.
21. Curtin N. 2007. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin. Ther. Targets 11: 783-799.
22. de Gonzalez AB, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E. 2011. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 12: 353-360.
23. De Grandis D. 2007. Acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 21(suppl. 1): 39-43.
24. Delaney CE, Hopkins SP, Addison CL. 2007. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett. 252: 195-207.
25. De Waele S, Van Belle S. 2010. Cancer-related fatigue. Acta Clin. Belg. 65: 378-385.
26. Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE. 2010. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br. J. Cancer 103: 1081-1084.
27. Draf C, Schaberg MR, Anand VK, Nyquist G, Hoda S. 2010. Radiation induced malignancy in retinoblastoma: new pathology in a case report. Laryngoscope 120(suppl. 4): S238.
28. Dreher D, Junod AF. 1996. Role of oxygen free radicals in cancer development. Eur. J. Cancer 32A: 30-38.
29. Elliott SP, Malaeb BS. 2011. Long-term urinary adverse effects of pelvic radiotherapy. World J. Urol. 29: 35-41.
30. Erel E, Vlachou E, Athanasiadou M, Hassan S, Chandrasekar CR, Peart F. 2010. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast 19: 424-427.
31. Fan JP, Kim HS, Han GD. 2009. Induction of apoptosis by l-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino Acids 36: 365-372.
32. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, Macluskey M, Pavitt S, Chan KK, Brocklehurst P; CSROC Expert Panel. 2010. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database Syst. Rev. 12: CD006387.
33. Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, Macciò A, Mantovani G. 2006. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22: 136-145.
34. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, De Gaetano A, Giordani P, Testa E, Lai V. 2002. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br. J. Cancer 86: 1854-1857.
35. Gulcin I. 2006. Antioxidant and antiradical activities of l-carnitine. Life Sci. 78: 803-11.
36. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fossa SD. 2010. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J. Clin. Oncol. 28: 4649-4657.
37. Heuberger W, Berardi S, Jacky E, Pey P, Krähenbühl S. 1998. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur. J. Clin. Pharmacol. 54: 503-508.
38. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, Mathieu MC, Marsiglia H, Bourgier C. 2010. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat. Oncol. 5: 104.
39. Hoang BX, Graeme Shaw D, Pham P, Levine S. 2007. Restoration of cellular energetic balance with l-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment. Med. Hypotheses 69: 262-272.
40. Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. 2009. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J. Pediatr. Hematol. Oncol. 31: 664-669.
41. Hosking FJ, Feldman D, Bruchim R, Olver B, Lloyd A, Vijayakrishnan J, Flint-Richter P, Broderick P, Houlston RS, Sadetzki S. 2011. Search for inherited susceptibility to radiation-associated meningioma by genomewide SNP linkage disequilibrium mapping. Br. J. Cancer 104: 1049-1054.
42. Hsieh CH, Chang HT, Lin SC, Chen YJ, Wang LY, Hsieh YP, Chen CA, Chong NS, Lin SL, Chen CY, Shueng PW. 2010. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment-case report. BMC Cancer 10: 696.
43. Hsin CH, Chen TH, Young YH, Liu WS. 2010. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol. Head Neck Surg. 143: 662-668.
44. Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. 2011. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother. Oncol. 98: 81-86.
45. Kang MK, Kim MS, Kim JH. 2010. Intraoperative radiotherapy for locally advanced rectal cancer. J. Korean Soc. Coloproctol. 26: 274-278.
46. Kanter M, Topcu-Tarladacalisir Y, Parlar S. 2010. Antiapoptotic effect of l-carnitine on testicular irradiation in rats. J. Mol. Histol. 41: 121-128.
47. Klaunig JE, Kamendulis LM. 2004. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44: 239-267.
48. Kocer I, Taysi S, Ertekin MV, Karslioglu I, Gepdiremen A, Sezen O, Serifoglu K. 2007. The effect of l-carnitine in the prevention of ionizing radiation-induced cataracts: a rat model. Graefes Arch. Clin. Exp. Ophthalmol. 245: 588-594.
49. Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V. 2010. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Acta Clin. Belg. 65: 300-304.
50. Lee SL. 2010. Complications of radioactive iodine treatment of thyroid carcinoma. J. Natl Compr. Cancer Netw. 8: 1277-1286.
51. Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Singh G, Pinthus JH. 2010. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int. J. Oncol. 37: 761-766.
52. Lindahl T, Nyberg B. 1972. Rate of depurination of native deoxyribonucleic acid. Biochemistry 11: 3610-368.
53. Linher-Melville K, Zantinge S, Sanli T, Gerstein H, Tsakiridis T, Singh G. 2011. Establishing a relationship between prolactin and altered fatty acid β-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer 2011 4; 11: 56.
54. Lissoni P, Galli MA, Tancini G, Barni S. 1993. Prevention by l-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy. Tumori 79: 202-204.
55. Loiselle C, Koh WJ. 2010. The emerging use of IMRT for treatment of cervical cancer. J. Natl Compr. Cancer Netw. 8: 1425-1434.
56. Madrid O, Varea S, Sanchez-Perez I, Gomez-Garcia L, De Miguel E, Gomez De Segura IA, Perona R. 2002. Growth hormone protects against radiotherapy-induced cell death. Eur. J. Endocrinol. 147: 535-541.
57. Malaguarnera M, Risino C, Gargante MP, Oreste G, Barone G, Tomasello AV, Costanzo M, Cannizzaro MA. 2006. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J. Gastroenterol. 12: 4541-4545.
58. Mancinelli A, D'Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M. 2007. Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment. Cancer Chemother. Pharmacol. 60: 19-26.
59. Mansour HH. 2006. Protective role of carnitine ester against radiation-induced oxidative stress in rats. Pharmacol. Res. 54: 165-171.
60. Mathews LA, Cabarcas SM, Farrar WL. 2011. DNA repair: the culprit for tumor-initiating cell survival? Cancer Metastasis Rev. 30: 185-197.
61. Mayer C, Popanda O, Greve B, Fritz E, Illig T, Eckardt-Schupp F, Gomolka M, Benner A, Schmezer P. 2011. A radiation-induced gene expression signature as a tool to predict acute radiotherapy-induced adverse side effects. Cancer Lett. 302: 20-28.
62. Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA. 2009. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30: 2-10.
63. Mescka C, Moraes T, Rosa A, Mazzola P, Piccoli B, Jacques C, Dalazen G, Coelho J, Cortes M, Terra M, Regla Vargas C, Dutra-Filho CS. 2011. In vivo neuroprotective effect of l-carnitine against oxidative stress in maple syrup urine disease. Metab. Brain Dis. 26: 21-28.
64. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. 2009. Receptor signaling as a regulatory mechanism of DNA repair. Radiother. Oncol. 92: 316-322.
65. Miles CL, Candy B, Jones L, Williams R, Tookman A, King M. 2007. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst. Rev. CD005540.
66. Palomera-Sanchez Z, Zurita M. 2011. Open, repair and close again: chromatin dynamics and the response to UV-induced DNA damage. DNA Repair 10: 119-125.
67. Pang D, Winters TA, Jung M, Purkayastha S, Cavalli LR, Chasovkikh S, Haddad BR, Dritschilo A. 2011. Radiation-generated sort DNA fragments may perturb non-homologous end-joining and induce genomic instability. J. Radiat. Res. 52: 309-319.
68. Patil VM, Kapoor R, Chakraborty S, Ghoshal S, Oinam AS, Sharma SC. 2010. Dosimetric risk estimates of radiation-induced malignancies after intensity modulated radiotherapy. J. Cancer Res. Ther. 6: 442-447.
69. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. 2000. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J. Cell. Physiol. 182: 339-350.
70. Peng G, Lin SY. 2011. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J. Clin. Oncol. 2: 73-79.
71. Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F. 2010. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-l-carnitine. Clin. Cancer Res. 16: 3944-3953.
72. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. 2005. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int. J. Radiat. Oncol. Biol. Phys. 63: 520-528.
73. Rizzo AM, Berselli P, Zava S, Montorfano G, Negroni M, Corsetto P, Berra B. 2010. Endogenous antioxidants and radical scavengers. Adv. Exp. Med. Biol. 698: 52-67.
74. Rogalidou M, Evangeliou A, Stiakaki E, Giahnakis E, Kalmanti M. 2010. Serum carnitine levels in childhood leukemia. J. Pediatr. Hematol. Oncol. 32: e61-69.
75. Sakata K, Someya M, Matsumoto Y, Hareyama M. 2007. Ability to repair DNA double-strand breaks related to cancer susceptibility and radiosensitivity. Radiat. Med. 25: 433-438.
76. Schlegel BP, Jodelka FM, Nunez R. 2006. BRCA1 promotes induction of ssDNA by ionizing radiation. Cancer Res. 66: 5181-5189.
77. Schötz U, Heuer S, Caldwell RB, Zitzelsberger H. 2011. Genetic and biochemical analysis of base excision repair complexes participating in radiation-induced ROS damage repair. Radiat. Prot. Dosim. 143: 284-288.
78. Sengupta S, Harris CC. 2005. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 6: 44-55.
79. Senkus E, Jassem J. 2011. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37: 300-311.
80. Sezen O, Ertekin MV, Demircan B, Karslioǧlu I, Erdoǧan F, Koçer I, Calik I, Gepdiremen A. 2008. Vitamin E and l-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages. Neurosurg. Rev. 31: 205-213.
81. Shahidi M, Mozdarani H, Mueller WU. 2010. Radiosensitivity and repair kinetics of gamma-irradiated leukocytes from sporadic prostate cancer patients and healthy individuals assessed by alkaline comet assay. Iran. Biomed. J. 14: 67-75.
82. Solarska K, Lewińska A, Karowicz-Bilińska A, Bartosz G. 2010. The antioxidant properties of carnitine in vitro. Cell. Mol. Biol. Lett. 15: 90-97.
83. Spotheim-Maurizot M, Davídková M. 2011. Radiation damage to DNA in DNA-protein complexes. Mutat. Res. 711: 41-48.
84. Sprung CN, Vasireddy RS, Karagiannis TC, Loveridge SJ, Martin RF, McKay MJ. 2010. Methylproamine protects against ionizing radiation by preventing DNA double-strand breaks. Mutat. Res. 692: 49-52.
85. Stewart FA, Hoving S, Russell NS. 2010. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat. Res. 174: 865-869.
86. Taddei PJ, Howell RM, Krishnan S, Scarboro SB, Mirkovic D, Newhauser WD. 2010. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys. Med. Biol. 55: 7055-7065.
87. Taylor CW, Nisbet A, McGale P, Darby SC. 2007. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int. J. Radiat. Oncol. Biol. Phys. 69: 1484-1495.
88. Topcu-Tarladacalisir Y, Kanter M, Uzal MC. 2009. Role of l-carnitine in the prevention of seminiferous tubules damage induced by gamma radiation: a light and electron microscopic study. Arch. Toxicol. 83: 735-746.
89. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. 2011. Low-dose γ-radiation-induced oxidative stress response in mouse brain and gut: regulation by NFκB-MnSOD cross-signaling. Mutat. Res. 718: 44-55.
90. Wang H, Yang ES, Jiang J, Nowsheen S, Xia F. 2010. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res. 70: 6258-6267.
91. West CM, Elliott RM, Burnet NG. 2007. The genomics revolution and radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19: 470-480.
92. Xu Y, Price BD. 2011. Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle 10: 261-267.
93. Yalman D, Demirci S, Bolukbasi Y, Caliskan C, Ozkok S. 2010. Postoperative radiotherapy in rectal cancer: long-term results of 290 patients. Hepatogastroenterology 57: 1099-1105.
94. Yaris N, Akyüz C, Coşkun T, Büyükpamukçu M. 2002. Serum carnitine levels of pediatric cancer patients. Pediatr. Hematol. Oncol. 19: 1-8.
95. Ye J, Li J, Yu Y, Wei Q, Deng W, Yu L. 2010. l-Carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul. Pept. 161: 58-66.
96. Zagar TM, Willett CG, Czito BG. 2010. Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology 24: 815-823, 828.
97. Zhang H, Gao XS, Zhao J, Xiong W, Zhang M, Li HZ, Zhou DM, Jin X, Zhang DS. 2010a. Differential gene expression profiles of DNA repair genes in esophageal cancer cells after X-ray irradiation. Chin. J. Cancer 29: 865-872.
98. Zhang Y, Chen LH, Wang L, Wang HM, Zhang YW, Shi YS. 2010b. Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells. Int. J. Radiat. Biol. 86: 964-974.